---
title: "Live Streaming Giant Dumps Short Drama Unit for AI Bet, While MedTech Rival Nails FDA Trial Green Light"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302959617.md"
description: "Ingkee offloads short-video unit for AI push as revenue drops 26%, while JetLife's tri-valve system secures FDA trial nod with sales surging 377%. One retreats from regulatory headwinds, the other charges into global markets."
datetime: "2026-10-24T09:13:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302959617.md)
  - [en](https://longbridge.com/en/news/302959617.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302959617.md)
generator: "portal-rs"
---

# Live Streaming Giant Dumps Short Drama Unit for AI Bet, While MedTech Rival Nails FDA Trial Green Light

While Ingkee (3700.HK) dumps its short-video unit for RMB 80 million to fund AI infrastructure, JetLife MedTech (9877.HK) is racing toward U.S. markets with FDA-approved clinical trials for its tri-valve system. The contrast couldn't be starker in Hong Kong's new consumption sector.

Ingkee's revenue plunged 26% in the first half of 2026 as live-streaming struggles intensified. The sale of Guangzhou KuaiChuang's stake—netting RMB 72.8 million—has redirected 75% of proceeds to AI development. Yet even as management touts a 59.1% gross margin from 'higher-margin short dramas,' hidden costs emerge: crypto asset write-downs swelled administrative expenses by 143%. Monthly active users fell 21%, but executives insist the pivot is working.

JetLife, meanwhile, has turned regulatory approvals into growth rocket fuel. With LuX-Valve Plus cleared for FDA trials and JensClip receiving NMPA approval, overseas sales now account for 46% of revenue. The 377% revenue surge in H1 2026 shrank losses by 71%—a sharp contrast to Ingkee's shrinking user base. As one company retreats from regulatory headwinds, the other charges into global markets with surgical precision.

### Related Stocks

- [03700.HK](https://longbridge.com/en/quote/03700.HK.md)
- [09877.HK](https://longbridge.com/en/quote/09877.HK.md)

## Related News & Research

- [Inkeverse files HKEX next-day disclosure return, issues 195,000,000 new shares at HKD 0.85 each](https://longbridge.com/en/news/292748430.md)
- [Inkeverse files HKEX next-day return reporting 192,488,400 new shares issued, lifting share capital](https://longbridge.com/en/news/291561415.md)
- [Jenscare Wins NMPA Approval for JensClip, Accelerates Global Valve Portfolio Push](https://longbridge.com/en/news/299760063.md)
- [Inkeverse H1 net profit drops 54% to RMB 126.09 million; revenue falls 26% to RMB 1.98 billion](https://longbridge.com/en/news/297299017.md)
- [Jenscare says LuX-Valve Plus wins Hong Kong health regulator approval](https://longbridge.com/en/news/298053021.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**